Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NorthSea Therapeutics BV

www.northseatherapeutics.com

Latest From NorthSea Therapeutics BV

Zydus Cadila First Off The Block In NASH After India Approval

Cadila Healthcare has received the first approval globally, in India, for a NASH therapy, after the national regulator cleared its candidate saroglitazar. The company also expects to begin Phase III trials in the US in the second quarter of fiscal 2021.

India Approvals

Venture Funding Deals: Generation Bio Raises $110m For Non-Viral Gene Therapies

Recent venture funding for emerging biopharma companies, including CF PharmTech, Codagenix, Empirico, Epirium, Generation, Kyverna, NorthSea, VectivBio, Rig and Tarsus. 

Deals Financing

Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

Financing Business Strategies

New Cash Moves NorthSea Up In NASH

With two new US investors on board, NST is financed to complete a Phase IIb trial of icosabutate in non-alcoholic steatohepatitis.

Financing Liver & Hepatic
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • NorthSea Therapeutics BV
  • Senior Management
  • Rob de Ree, CEO
    Mats Blom, CFO
    David A Fraser, PhD, CSO
    Hilde H Steineger, PhD, COO
    Patrick Round, MD, CMO
  • Contact Info
  • NorthSea Therapeutics BV
    Phone: 35 760 65 05
    Gooimeer 2-35
    Naarden, 1411 DC
    Netherlands
UsernamePublicRestriction

Register